HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

506.075

-10.940-2.12%

Number of Gainers:9

Number of Losers:21

Number of Flat:3

PE:- -

High:516.490

Open:516.490

Low:500.597

Close:517.015

Volume:149.97M

Turnover:4.87B

Market Cap:324.25B

Float Cap:288.12B

Loading ...

Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call

Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call

BioDlink International (SEHK:1875) Stock Rebound Meets Shrinking Revenue And Fresh Losses

Simply Wall St.

Peijia Medical (SEHK:9996) Stock Nears Breakeven As Revenue Momentum Builds

Simply Wall St.

Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms

Simply Wall St.

Keymed Biosciences Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Simply Wall St.

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

IMMUNOTECH-B Reports Half-Year Results with Narrowed Loss

Immunotech Biopharm FY26 H1 Net Loss Narrows 45.8% to RMB 69.87 Million

PEIJIA-B Reports 20.1% Revenue Growth in Interim Results

Peijia Medical H1 FY26 Loss Narrows 87.4% to RMB 8.99 Million; Revenue Rises 20.1% to RMB 424.5 Million

Edding Genor Group Expects Revenue of Rmb850 MLN-Rmb900 MLN for HY

Edding Genor Expects H1 Net Loss of RMB 60 Million-RMB 70 Million vs Year-Ago Profit

Jhbp Cy - Expects Revenue of Rmb850 Mln-Rmb900 Mln for Six Months Ended 30 June 2026

THOMSON REUTERS

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million

Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY

THOMSON REUTERS

Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":506.0749,"timestamp":1787299686774,"preClose":517.0147,"halted":0,"volume":149966252,"delay":0,"changeRate":-0.02116,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-10.939819,"latestTime":"08-21 16:00:00","open":516.49023,"high":516.49023,"low":500.59692,"amount":4865243342.5,"amplitude":0.030741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"pbRate":4.109535,"peRate":-81.157718,"turnoverRate":0.005372,"increases":11,"decrements":20,"flats":2,"marketCap":324245256080,"floatMarketCap":288118014384},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":516.49023,"amplitude":0.030741,"preClose":517.0147,"low":500.59692,"pbRate":"4.109535","latestPrice":506.0749,"volume":149966252,"delay":0,"open":516.49023,"prevYearClose":556.26263,"prevWeekClose":518.327,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":518.327,"twentyDayClose":498.407,"sixtyDayClose":542.586,"secType":"PLATE","market":"HK","turnoverRate":0.005372,"peRate":-81.157718,"marketCap":324245256080,"floatMarketCap":288118014384,"timestamp":1787299686774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":9,"down":21,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143799433","title":"Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1143799433","media":"Deep News","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143799433?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:50","pubTimestamp":1787460624,"startTime":"0","endTime":"0","summary":"Citi has released a research report stating that KEYMED BIO-B (02162) posted first-half 2026 revenue of RMB 617 million, up 24% year-on-year. Within that total, sales of stapokibart reached RMB 393...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","IE00BSNM7G36.USD","LU1506573853.SGD","LU0128525689.USD","LU1074936037.SGD","LU2125154935.USD","LU2456880835.USD","BK1574","LU0162691827.USD","IYF","BK4559","BK4207","BK4588","C","LU1366192091.USD","LU0170899867.USD","BK1583","LU0203345920.USD","LU1162221912.USD","LU2125154778.USD","LU1244550577.SGD","LU0320765646.SGD","LU0106831901.USD","BK4504","BK4534","LU0314106906.USD","LU0098860793.USD","LU1244550221.USD","BK1587","LU0130102774.USD","LU0072461881.USD","BK1161","LU0052756011.USD","LU0130517989.USD","02162","LU1201861249.SGD","LU1668664300.SGD","LU2236285917.USD","LU0310800965.SGD","LU0980610538.SGD","FTXO","LU0648001328.SGD","LU1791807156.HKD","EWH","TFNS","BK4566","LU2462157665.USD","LU0203347892.USD","LU2360032135.SGD","LU1144417596.USD","LU1244550494.USD","LU1267930227.SGD","LU0477156953.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174192289","title":"Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1174192289","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174192289?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:40","pubTimestamp":1787460029,"startTime":"0","endTime":"0","summary":"Daiwa has released a research report stating that KEYMED BIO-B (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","EWH","BK1587","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661121751","title":"BioDlink International (SEHK:1875) Stock Rebound Meets Shrinking Revenue And Fresh Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661121751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661121751?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:30","pubTimestamp":1787445032,"startTime":"0","endTime":"0","summary":"BioDlink International has been trading like a recovery story, with the stock up about 17% over the past month. However, H1 2026 results underline that this is still a loss making biotech with a valuation built on hope rather than profit. The headline this half is the profit squeeze. Revenue came in at ¥246.011 million, while net income excluding extra items showed a loss of ¥58.517 million and basic earnings per share were also in the red. The share price reaction now rests on how long...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1875/biodlink-international-shares/news/biodlink-international-sehk1875-stock-rebound-meets-shrinkin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1875/biodlink-international-shares/news/biodlink-international-sehk1875-stock-rebound-meets-shrinkin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GXDW","RGLO","FEBU","VOTE","BK1574","BK1161","VGFPF","DECU","01875","JOYT","PMDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217313","title":"Peijia Medical (SEHK:9996) Stock Nears Breakeven As Revenue Momentum Builds","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217313","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661217313?lang=en_us&edition=fundamental","pubTime":"2026-08-23 07:18","pubTimestamp":1787440688,"startTime":"0","endTime":"0","summary":"Peijia Medical stock closed at HK$4.98 on the day of its H1 2026 release after a choppy few months that left the 90 day return in decline. The market came in focused on whether the company could keep shrinking losses while still pushing top line growth in high end cardiovascular devices.\nThe headline is that Peijia Medical is selling more while bleeding far less. Revenue for H1 2026 reached ¥424.5m, while the net loss narrowed sharply to ¥7.6m. For long term investors in this still...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-9996/peijia-medical-shares/news/peijia-medical-sehk9996-stock-nears-breakeven-as-revenue-mom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-9996/peijia-medical-shares/news/peijia-medical-sehk9996-stock-nears-breakeven-as-revenue-mom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1100","09996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212911","title":"Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212911","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661212911?lang=en_us&edition=fundamental","pubTime":"2026-08-23 04:28","pubTimestamp":1787430511,"startTime":"0","endTime":"0","summary":"The market has spent the past week marking Antengene lower, with the stock down about 10% over seven days, yet the latest numbers tell a very different story. H1 2026 landed with a sharp swing into profit, with basic earnings per share at ¥0.34 and net income of ¥216.345 million on revenue of ¥513.076 million. For a high P/E stock trading at about 42.4x trailing earnings, this move into the black is the headline. The key question now is whether this profitability burst can justify that...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-stock-drops-as-profit-arrives-and-valuati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-stock-drops-as-profit-arrives-and-valuati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06996","GXDW","BK1574","JOYT","RGLO","VGFPF","FEBU","VOTE","BK1191","PMDE","BK1583","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661215890","title":"Keymed Biosciences Inc. Just Missed Earnings - But Analysts Have Updated Their Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2661215890","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661215890?lang=en_us&edition=fundamental","pubTime":"2026-08-22 07:01","pubTimestamp":1787353294,"startTime":"0","endTime":"0","summary":"Investors in Keymed Biosciences Inc. ( HKG:2162 ) had a good week, as its shares rose 2.8% to close at HK$80.30...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-just-missed-earnings-but-analysts-hav","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-just-missed-earnings-but-analysts-hav","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1587","GXDW","JOYT","02162","VGFPF","FEBU","PMDE","BK1574","RGLO","VOTE","DECU","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661901362","title":"Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661901362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661901362?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:15","pubTimestamp":1787346928,"startTime":"0","endTime":"0","summary":"Niki BioSolutionsweighs financing options as going-concern warning clouds post-merger outlookOverviewUS biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6Operating expenses","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","IE00BZ08YT58.USD","BK1574","BK1191","02137","BK1587","01177","BK1589","BK4139","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR","BK1521","BK1583","HK0000165453.HKD","NIKI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661297920","title":"Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020","url":"https://stock-news.laohu8.com/highlight/detail?id=2661297920","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661297920?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:17","pubTimestamp":1787343447,"startTime":"0","endTime":"0","summary":"Zai Lab CFO Chen Yajing sells 260 ADS worth $7,020Zai Lab CFO Chen Yajing sold 260 American Depositary Shares on Aug. 19, 2026 at USD 27.Post-transaction holdings totaled 35,635 ADS, held directly.Tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLN7hqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","BK1574","09688","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661291392","title":"Ascletis Pharma Expects HY Loss of Rmb319.7 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291392","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291392?lang=en_us&edition=fundamental","pubTime":"2026-08-21 23:45","pubTimestamp":1787327122,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Expects HY Loss Of RMB319.7 MLNAug 21 (Reuters)-Ascletis Pharma Inc1672.HK:EXPECTS LOSS OF RMB319.7 MILLION FOR H1 2026, UP 263.5% YOYEXPECTED HY RESULT AS RESEARCH AND DEVELOPMENT EXPENSES INCREASED 132.7% TO RMB341.7 MILLION, OTHERSFurther company coverage:1672.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120386450","title":"IMMUNOTECH-B Reports Half-Year Results with Narrowed Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1120386450","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120386450?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:38","pubTimestamp":1787323092,"startTime":"0","endTime":"0","summary":"IMMUNOTECH-B (06978) has released its interim financial results for the six months ended June 30, 2026, revealing a significant improvement in its bottom line.During the period, the group recorded...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229618","title":"Immunotech Biopharm FY26 H1 Net Loss Narrows 45.8% to RMB 69.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229618","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661229618?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:30","pubTimestamp":1787322610,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm FY26 H1 net loss narrows 45.8% to RMB 69.87 millionImmunotech Biopharm reported a first-half loss attributable to owners of RMB 69.87 million, narrowing 45.9% year over year.Basic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL2vNB0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126074349","title":"PEIJIA-B Reports 20.1% Revenue Growth in Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1126074349","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126074349?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:18","pubTimestamp":1787321897,"startTime":"0","endTime":"0","summary":"PEIJIA-B (09996) has announced its interim results for 2026, with revenue reaching RMB 425 million, representing a year-on-year increase of 20.1%. Gross profit climbed 17.13% to RMB 290 million,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","09996","BK1574","BK1100","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295247","title":"Peijia Medical H1 FY26 Loss Narrows 87.4% to RMB 8.99 Million; Revenue Rises 20.1% to RMB 424.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295247","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661295247?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:08","pubTimestamp":1787321303,"startTime":"0","endTime":"0","summary":"Peijia Medical H1 FY26 loss narrows 87.4% to RMB 8.99 million; revenue rises 20.1% to RMB 424.5 millionPeijia Medical posted revenue of RMB 424.5 million, up 20.1% year over year, in the six months en","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL97k65j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","09996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729592","title":"Edding Genor Group Expects Revenue of Rmb850 MLN-Rmb900 MLN for HY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729592","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:59","pubTimestamp":1787320752,"startTime":"0","endTime":"0","summary":"BRIEF-Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HYAug 21 (Reuters)-Edding Genor Group Holdings Ltd6998.HK:EXPECTS REVENUE OF RMB850 MILLION-RMB900 MILLION FOR SIX MONTHS ENDED 30 JUNE 2026Further company coverage:6998.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","06998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661947295","title":"Edding Genor Expects H1 Net Loss of RMB 60 Million-RMB 70 Million vs Year-Ago Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2661947295","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661947295?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:57","pubTimestamp":1787320646,"startTime":"0","endTime":"0","summary":"Edding Genor expects H1 net loss of RMB 60 million-RMB 70 million vs year-ago profitEdding Genor flagged a first-half swing to loss, citing weaker sales, higher R&D spending, and pricing pressure expe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL47Ym1v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","06998","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295943","title":"Jhbp Cy - Expects Revenue of Rmb850 Mln-Rmb900 Mln for Six Months Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661295943?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:57","pubTimestamp":1787320627,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","06998","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188138907","title":"Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1188138907","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188138907?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:22","pubTimestamp":1787314947,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has issued a profit warning, forecasting a net loss attributable to equity shareholders of approximately RMB 319.7 million for the six months ending June 30, 2026. This...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","BK1574","BK1161","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661115260","title":"Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661115260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661115260?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:01","pubTimestamp":1787313666,"startTime":"0","endTime":"0","summary":"Ascletis Pharma sees H1 loss widening to RMB 319.7 millionAscletis flagged a wider loss attributable to equity shareholders of about RMB 319.7 million for the six months ended June 30, 2026.Compares w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL949XQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260941","title":"Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260941?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01672","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260157","title":"Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260157?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":286,"code":"91000000","status":"200"}]}}